Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients

BACKGROUND: Targeted therapy with tyrosine kinases inhibitors (TKIs) against epidermal growth factor receptor (EGFR) is part of routine clinical practice for EGFR mutant advanced non-small cell lung cancer (NSCLC) patients. These patients eventually develop resistance, frequently accompanied by a ga...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexeyenko, Andrey, Brustugun, Odd Terje, Eide, Inger Johanne Zwicky, Gencheva, Radosveta, Kosibaty, Zeinab, Lai, Yi, de Petris, Luigi, Tsakonas, Georgios, Grundberg, Oscar, Franzen, Bo, Viktorsson, Kristina, Lewensohn, Rolf, Hydbring, Per, Ekman, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641044/
https://www.ncbi.nlm.nih.gov/pubmed/36386450
http://dx.doi.org/10.21037/tlcr-22-236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641044/
https://www.ncbi.nlm.nih.gov/pubmed/36386450
http://dx.doi.org/10.21037/tlcr-22-236

Ejemplares similares